UMCG and MIcompany start cross-border collaboration

In 2025, 50% of Europeans are expected to suffer from Asthma or other chronic allergic disease. That’s one of the reasons MIcompany has started a collaboration with the UMCG (Universitair Medisch Centrum Groningen) in the field of DNA research to unravel the mysteries behind asthma and other allergic diseases. In a joint research team we strive for medical breakthroughs that enable better prediction of allergy risk and insights for the development of new medicines. This cross-border collaboration is described in the attached PDF article, revealing the exciting opportunities and medical relevance of DNA research.

Interested to find out more? We also attached a double-interview in the Financieel Dagblad with the initiators of this collaboration, prof. dr. Gerard Koppelman of the UMCG and MIcompany founder Marnix Bügel PhD.

 

Press release UMCG, DNA project MIcompany (EN)

Online artikel het Financieel Dagblad (NL)

Krantenartikel het Financieel Dagblad (NL)

DNA artikel krant van het Noorden (NL)